Alpha-0261 tablets for chronic spontaneous urticaria and effect of food in healthy adults
Tests Alpha-0261 tablets in adults with chronic spontaneous urticaria and healthy volunteers.
Key facts
- Who runs it
- AlphaMol Science Ltd. (Shanghai)
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Alpha-0261
- Placebo
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no known trigger) for Part 1. It is also looking for healthy adults for Part 2, which tests the effect of food.
- Age
- Part 1: 18 to 75 years. Part 2: 18 to 55 years.
- Sex
- Men and women can join.
- Disease stage
- Part 1: chronic spontaneous urticaria diagnosed at least 6 months before screening. Part 2: in general good health, weight ≥ 50 kg (110 lb) for men and ≥ 45 kg (99 lb) for women, BMI 19 kg/m2 to 28 kg/m2.
- Earlier treatment
- Part 1: stable second-generation H1 antihistamine therapy for at least 2 weeks before randomization. People must be willing to keep it unchanged during the study.
Main reasons for not taking part
- Part 1: hives with a clear trigger, such as cold, heat, sun, pressure, water, sweating or scratching the skin.
- Part 1: other long-lasting itchy skin diseases, such as atopic dermatitis or psoriasis.
- Part 1: other conditions that can cause hives or swelling, such as urticarial vasculitis, mastocytosis or drug-induced urticaria.
- Part 2: any past severe allergic reaction or anaphylaxis.
- Part 2: clearly abnormal lab test results.
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Written informed consent must be obtained before any assessment is performed.(Part 1 and Part 2)
- Aged ≥ 18 and ≤ 75, male or female (Part 1)
- Diagnosed with CSU prior to screening at least 6 months. (Part 1)
- Received stable second-generation H1 antihistamine therapy for at least 2 weeks before randomization, and is willing to maintain the stable treatment regimen throughout the study treatment period. (Part 1)
- Aged ≥ 18 and ≤ 55, male or female (Part 2)
- Weight: ≥ 50 kg for males, ≥ 45 kg for females; 19 kg/m2 ≤ body mass index (BMI) ≤ 28 kg/m2. (Part 2)
- In general good health. (Part 2)
Who cannot take part
- Other chronic pruritic skin diseases that may affect the assessment of study outcomes, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or psoriasis. (Part 1)
- Other conditions that may cause urticaria or angioedema symptoms, including but not limited to urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticaria. (Part 1)
- Have a history of any severe allergic reaction or anaphylaxis. (Part 2)
- Any condition, which in the investigator's opinion might jeopardize articipant's safety or compliance with the protocol. (Part 2)
- Have clinically significant abnormalities on clinical laboratory results. (Part 2)
- Inducible urticaria with identifiable triggers, including dermographism, cold contact urticaria, heat contact urticaria, solar urticaria, pressure urticaria, delayed pressure urticaria, aquagenic urticaria, cholinergic urticaria, or contact urticaria. (Part 1)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Alpha-0261 Tablets in healthy Chinese adults and in patients with chronic spontaneous urticaria.
The 3 groups in the trial
- Multiple Ascending Dose (Part 1)Treatment being tested
50 mg (25 mg tablet), 125 mg (125 mg tablet), 250 mg (125 mg tablet), and 500 mg (125 mg tablet) of Alpha-0261 will be administered QD for 4 weeks, orally to subjects in the treatment group, cohort 1 to 4.
Treatment: Alpha-0261
- Placebo (Part 1)Placebo, for comparison
Matched placebo control of cohort 1 to 4.
Treatment: Placebo
- Single Dose (Part 2)Treatment being tested
Single Dose of Alpha-0261. Alpha-0261 is administered once per treatment cycle. Two treatment cycles.
Treatment: Alpha-0261
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.
- Plain-language title
- Alpha-0261 tablets for chronic spontaneous urticaria and effect of food in healthy adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07684560, who can take part
- Record updated
- 6 July 2026